EMA Authorised: Kadcyla (trastuzumab emtansine) — Roche Registration GmbH

View source ↗

Summary

Kadcyla (trastuzumab emtansine) by Roche Registration GmbH has been authorised for use in the European Union for breast neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Breast Neoplasms

Drugs mentioned

• Kadcyla (ado-trastuzumab emtansine)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms. MAH: Roche Registration GmbH. Decision date: 16/06/2026